Recognizing Advanced Alzheimer’s: Signs, Support, and Care
Alzheimer’s disease is a complex journey, both for those experiencing it and their caregivers. Early in the condition, a person will experience mild memory…
Alzheimer’s disease is a complex journey, both for those experiencing it and their caregivers. Early in the condition, a person will experience mild memory…
This article was made possible through sponsorship by Alzheon. Being Patient’s editorial team produced the interview with no review/approval process by the sponsor. Alzheimer’s…
Alzheimer’s is a condition affecting more than 30 million people worldwide. It causes problems with language, memory, and cognition. While scientists aren’t 100 percent…
Dementia is often thought of as a memory problem, like when an older adult asks the same questions or misplaces things. In reality, individuals…
Is dementia preventable? Research shows that yes, sometimes, it is. Scientists project that the number of people living with dementia, a neurodegenerative syndrome which…
Mild Cognitive Impairment (MCI) is associated with early stages of neurodegenerative diseases like Alzheimer’s and other dementias. Many people living with dementia cite symptoms…
Editor’s note: Dr. Marwan Sabbagh will join Being Patient again on September 19, 2023 to revisit this topic and discuss dementia misdiagnosis, why it’s…
There are a number of different ways that COVID-19 can leave its mark on the brain. Some are life-threatening — from severe brain-swelling to…
When you have a family member living with dementia, one of the hardest things to consider is when it’s time to take away the…
Vaccines are one of the greatest medical advances in history, and now, this strategy is being applied to the treatment and prevention of Alzheimer’s….
This article is part of the series Diversity & Dementia, produced by Being Patient with support provided by Eisai. Dr. Indira Turney was born in the…
There are dozens of new approaches to treating Alzheimer’s currently in clinical trials. But while some promising innovations in diagnostics and intervention are progressing…
Alzheimer’s disease affects one in every three people over the age of 85, and the scale of the epidemic is only worsening. While there…
In January of 2023, the Food and Drug Administration approved the second anti-amyloid therapy for Alzheimer’s disease, Leqembi (generic name lecanemab). A new Alzheimer’s…
Age is the major risk factor for Alzheimer’s — approximately 10 percent of people over the age of 65 develop the disease. As cases…